Advertisement
REPL vs ZYME
Which Stock Would AI Choose? Replimune Group (REPL) vs. Zymeworks (ZYME) Stock Comparison
Key Takeaways
- Replimune Group (REPL) is a pre-revenue clinical-stage biotech whose shares are driven almost entirely by binary regulatory catalysts for its lead drug candidate, RP1.
- Zymeworks (ZYME) is a more diversified biotech with an FDA-approved product, royalty and milestone income, and a completed acquisition that adds commercial revenue.
- REPL's stock has experienced extreme volatility tied to FDA decisions, while ZYME has shown more measured, fundamentally supported price action.
- The two names represent contrasting risk profiles: a high-beta catalyst play versus a revenue-diversifying, cash-flow-oriented operator.
- Tickeron's AI framework tends to favor consistency and stability, which shapes how these two stocks compare on trend and positioning.
Introduction
Both REPL and ZYME operate in oncology-focused biotechnology, yet they sit at very different stages of commercial maturity and face different drivers of sentiment. This stock comparison is relevant for investors weighing a high-upside, high-volatility clinical-stage name against a more diversified, revenue-generating counterpart. Because the two companies differ sharply in business model, cash-flow profile, and regulatory risk, a side-by-side look at their relative performance and market positioning can help clarify which better suits a given trading or investing approach in the current market environment.
REPL Overview and Recent Performance
Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies, with lead candidate RP1 (vusolimogene oderparepvec) intended to treat advanced melanoma in combination with the checkpoint inhibitor nivolumab. The company has no approved products, so its share price has been dominated by regulatory events.
Recent market activity has been exceptionally volatile. After the U.S. Food and Drug Administration (FDA) issued Complete Response Letters (CRLs) in July 2025 and again in April 2026 declining to approve the RP1 Biologics License Application (BLA, a request for permission to market a biologic drug), shares fell sharply. Sentiment reversed in recent weeks after Replimune and the FDA aligned on a BLA resubmission path, and the FDA later accepted the resubmission and prioritized its review. A subsequent advisory committee vote found the IGNYTE study efficacy results evaluable and clinically meaningful, prompting a substantial rally and several analyst upgrades.
As of March 31, 2026, Replimune reported cash and short-term investments of approximately $268.9 million, which management expects to fund operations into the first quarter of calendar 2027. The company also disclosed a net loss of roughly $313.9 million for its fiscal year ended March 31, 2026. A securities class action naming the company remains pending, adding a layer of litigation-related uncertainty.
ZYME Overview and Recent Performance
Zymeworks is a global biotechnology company that develops multifunctional antibody therapeutics, including bispecific antibodies and antibody-drug conjugates (ADCs, which link a cancer-killing drug to a targeting antibody). Its lead asset, Ziihera (zanidatamab), targets HER2-positive (HER2 is a growth-driving protein) gastroesophageal adenocarcinoma and is partnered with Jazz Pharmaceuticals and BeOne Medicines. The FDA granted a second approval for zanidatamab in recent weeks, covering first-line treatment.
Beyond its pipeline, Zymeworks has pursued a strategy of diversifying cash flows. In recent weeks it completed the acquisition of Theravance Biopharma for roughly $929 million in equity value, adding the commercial product YUPELRI for chronic obstructive pulmonary disease and approximately $60 million in expected annualized cash flow. The company has also operated an active share repurchase program, authorizing up to $125 million in 2026.
Zymeworks reported $322.5 million in cash and marketable securities as of June 30, 2026. Its financial profile includes milestone-dependent revenue, which can be lumpy quarter to quarter, but the Theravance transaction is intended to smooth earnings and move the company toward durable, revenue-generating operations.
Trending AI Robots
For investors who prefer a systematic approach to navigating volatile biotech names, Tickeron's Trending AI Robots page offers a curated view of the platform's automated strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only a small subset earns a place in this section. At the time of writing, the page highlights a select group of roughly 21 top bots chosen from a broader universe of about 324, with reported metrics spanning realized returns, win rates, profit factors, and average trade durations. Each bot uses a distinct trading style, strategy, timeframe, and set of tickers, so no two are interchangeable. Exploring the Trending AI Robots page can help traders identify which automated strategies align with current market conditions.
Head-to-Head Comparison
The sharpest contrast between these two names is maturity. REPL remains pre-revenue, with its near-term fate tied to a single regulatory decision and confirmatory clinical data. That concentration creates outsized upside potential but also elevated drawdown risk, as demonstrated by the stock's wide price swings around FDA milestones. ZYME, by contrast, already has an approved, partnered product and is layering on commercial cash flow through acquisition, giving it a more stable revenue trajectory and lower dependence on any single catalyst.
Growth drivers also differ. REPL's thesis rests on RP1 gaining accelerated approval and eventual commercialization, plus pipeline expansion into other skin cancers. ZYME's thesis combines royalty and milestone income, ADC pipeline advancement, and the integration of Theravance's assets. On risk factors, REPL carries concentrated regulatory and litigation risk, while ZYME faces integration execution risk and the inherent lumpiness of milestone-based revenue. Sector exposure is similar (oncology biotech), but market sentiment currently rewards ZYME's diversified, cash-generating positioning over REPL's binary catalyst profile.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI framework would likely favor ZYME in the current environment. Its scoring emphasizes trend consistency, relative stability, and diversification of catalysts, all of which favor a revenue-generating operator with a completed acquisition and an active buyback over a pre-revenue company whose near-term value hinges on a single regulatory outcome. That said, REPL's recent positive FDA momentum could register as a short-term trend signal. The comparative edge, however, tilts toward ZYME on the basis of steadier fundamentals and less concentrated downside risk.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REPL is a Buy and ZYME is a Buy.
REPL in upward trend: price rose above 50-day moving average on October 28, 2026
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 60 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for REPL just turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 40 of 49 cases over the following month. The odds of a continued upward trend are 82%.
The 10-day moving average for REPL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +7.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 183 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.282) is normal, around the industry mean (3.498). P/E Ratio (-6.863) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ZYME in upward trend: price rose above 50-day moving average on October 20, 2026
ZYME moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ZYME as a result. In 72 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for ZYME just turned positive on October 20, 2026. Looking at past instances where ZYME's MACD turned positive, the stock continued to rise in 43 of 48 cases over the following month. The odds of a continued upward trend are 90%.
The 10-day moving average for ZYME crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 17 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZYME advanced for three days, in 252 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for ZYME moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator moved out of overbought territory. In 44 of the 53 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
ZYME broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZYME entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 79 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.452) is normal, around the industry mean (3.498). P/E Ratio (-14.668) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
REPL | ZYME | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 47 | 45 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 79 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 34 | 36 | |
P/E GROWTH RATING 1..100 | 98 | 76 | |
SEASONALITY SCORE 1..100 | 50 | 7 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REPL's Valuation (83) in the Biotechnology industry is in the same range as ZYME (83) in the Pharmaceuticals Major industry. This means that REPL’s stock grew similarly to ZYME’s over the last 12 months.
ZYME's Profit vs Risk Rating (79) in the Pharmaceuticals Major industry is in the same range as REPL (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to REPL’s over the last 12 months.
ZYME's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as REPL (99) in the Biotechnology industry. This means that ZYME’s stock grew similarly to REPL’s over the last 12 months.
REPL's Price Growth Rating (34) in the Biotechnology industry is in the same range as ZYME (36) in the Pharmaceuticals Major industry. This means that REPL’s stock grew similarly to ZYME’s over the last 12 months.
ZYME's P/E Growth Rating (76) in the Pharmaceuticals Major industry is in the same range as REPL (98) in the Biotechnology industry. This means that ZYME’s stock grew similarly to REPL’s over the last 12 months.
| REPL | ZYME | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 84% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 84% |
| Advances ODDS (%) | 2 days ago 75% | 2 days ago 85% |
| Declines ODDS (%) | 29 days ago 84% | 13 days ago 81% |
| BollingerBands ODDS (%) | 2 days ago 74% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 80% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
REPL’s FA Score shows that 0 FA rating(s) are green while ZYME’s FA Score has 0 green FA rating(s).
- REPL’s FA Score: 0 green, 5 red.
- ZYME’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
REPL’s TA Score shows that 5 TA indicator(s) are bullish while ZYME’s TA Score has 5 bullish TA indicator(s).
- REPL’s TA Score: 5 bullish, 5 bearish.
- ZYME’s TA Score: 5 bullish, 5 bearish.
Price Growth
REPL (@Biotechnology) experienced а +12.74% price change this week, while ZYME (@Biotechnology) price change was +4.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
REPL is expected to report earnings on Feb 02, 2027.
ZYME is expected to report earnings on Mar 10, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ZYME and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with JAZZ. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then JAZZ could also see price increases.
| Ticker / NAME | Correlation To ZYME | 1D Price Change % | ||
|---|---|---|---|---|
| ZYME | 100% | +2.11% | ||
| JAZZ - ZYME | 53% Loosely correlated | +0.77% | ||
| REPL - ZYME | 46% Loosely correlated | +4.58% | ||
| ENTA - ZYME | 44% Loosely correlated | -2.18% | ||
| VSTM - ZYME | 44% Loosely correlated | +0.34% | ||
| DYN - ZYME | 42% Loosely correlated | -3.76% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SRTY | 25.61 | 0.51 | +2.03% |
| ProShares UltraPro Short Russell2000 (SRTY) | |||
| TDV | 102.99 | 0.27 | +0.27% |
| ProShares S&P Technology Dividend Aristocrats ETF (TDV) | |||
| PWRL | 11.32 | N/A | N/A |
| Powerlaw Corp | |||
| SPIT | 29.20 | -0.09 | -0.32% |
| F/m Emerald Special Situations ETF (SPIT) | |||
| VOTE | 88.36 | -0.34 | -0.39% |
| TCW Transform 500 ETF (VOTE) | |||